Christopher Richard Anzalone - 07 Jul 2022 Form 4 Insider Report for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Role: Chief Executive Officer, Director
Signature: /s/Christopher Anzalone
Issuer symbol: ARWR
Transactions as of: 07 Jul 2022
Net transactions value: +$36,365
Form type: 4
Filing time: 11 Jul 2022, 20:08:32 UTC
Previous filing: 14 Feb 2022
Next filing: 12 Jul 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ARWR	Common Stock	Options Exercise	$36,365	+2,501	+0.06%	$14.54	4,060,135	07 Jul 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ARWR	Stock Option (right to buy Common Stock)	Options Exercise	$0	-2,501	-0.41%	$0.000000	612,532	07 Jul 2022	Common Stock	2,501	$14.54	Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes a total of 2,300,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance and/or market-based goals. If the goals are not met within the required time periods, the awards will be forfeited in part or in whole.
F2	Represents first vesting date. Option vested over four years from date of grant.
F3	Represents total stock options beneficially owned at various strike prices.